Authors


Meir Rinde, MS

Latest:

Making Patients in Canada Switch to Etanercept Biosimilars Caused No Harm or Changes in Health Care Use, Study Finds

Health Canada approved biosimilars Brenzys and Erelzi in August 2016 and April 2017, respectively. The study tracked effects of the first phase of the British Columbia Ministry of Health’s Biosimilar Initiative, which required patients to switch to biosimilars starting in May 2019.


Rose McNulty

Latest:

Fresenius Kabi's Tocilizumab Biosimilar, Tyenne, Launches in US Market

Tyenne (tocilizumab-aazg) was the second tocilizumab biosimilar to be FDA approved, but it is the first to launch in the US.


Anna Chen, PharmD, MS

Latest:

Budget Impact Analysis of Biosimilar Natalizumab in the US

Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.


St John Skilton, PhD

Latest:

Contributor: The Biosimilars Wave Is Crashing on the Shores of Biopharma Development

St John Skilton, PhD, vice president of product strategy and marketing at Protein Metrics, takes a deep dive into how the development of biosimilars is evolving and how tools, such as mass spectrometry, can help companies keep up with advancing technology.


Robert Zutaut, RPh

Latest:

Pharmacy Can Help Drive Adoption of Rheumatoid Arthritis Biosimilars

Pharmacists will have the opportunity to use their knowledge of biosimilars to reinforce their benefits, safety, and efficacy.


Wayne Winegarden, PhD

Latest:

Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?

If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.


Ha Kung Wong
Ha Kung Wong, JD

Latest:

Contributor: The Trouble With IP for Digital Health and Precision Medicine

Two experts in biosimilar intellectual property (IP) law break down the issues that digital health and precision medicine face with IP and the history of case law that has created the current landscape.


Kostas Botsoglou, MD

Latest:

Resources for Patients and Providers on Adalimumab Biosimilars

Expert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.


Juliana M. Reed

Latest:

Americans Say Drug Costs Are Too High, and They Are Right

The executive director of the Biosimilars Forum calls for policies to support adoption of lower-cost biologics.


Ashley Gallagher

Latest:

Dr Lakesha Farmer Highlights Current Biosimilar Education, Acceptance Efforts

Cencora's Lakesha Farmer, PharmD, MBA, discusses efforts that health care organizations can take to better educate patients and providers on biosimilars to improve biosimilar acceptance and achieve cost savings associated with these products.


Ted Mathias, JD

Latest:

Opinion: Purple Book Patent Listings Are Only a First Step

Intellectual property attorneys from Axinn discuss the limitations of the Purple Book patent disclosure requirements and the burden these impose on biosimilar developers.


Edward Li, PharmD, MPH

Latest:

Budget Impact Analysis of Biosimilar Natalizumab in the US

Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.


Craig Burton

Latest:

Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar Competition

In response to another opinion piece, Craig Burton, from the Association for Accessible Medicines, argued that the Inflation Reduction Act of 2022 could prevent biosimilar competition, and lower drug prices as a result.


Marion Schauf, Dipl-Kff

Latest:

Budget Impact Analysis of Biosimilar Natalizumab in the US

Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.









Amanda DeMarzo, PharmD, MBA, PACS

Latest:

The Pandemic's Multilevel Effect on Patient Access

Coronavirus disease 2019 altered the workflow in all areas of the health care and life sciences industries, and the FDA was not exempt from pandemic-induced upheaval.




Tony Hagen

Latest:

AmerisourceBergen Rep Previews the Year Ahead for Biosimilars: What’s Coming Down the Pipeline in 2022?

Sean McGowan, senior director of Biosimilars for AmerisourceBergen, forecasts potential biosimilar approvals and launches in 2022 as well as offers insights into how emerging biosimilars will impact the market and pricing in the coming years during an interview.


Steven Lucio, PharmD, BCPS

Latest:

Understanding the Risks, Opportunities, and Prospects of Biosimilars in 2020 and Beyond

Hurdles to a vibrant biosimilar market are not as insurmountable as they appear.



Skylar Jeremias

Latest:

Eye on Pharma: High-Strength Trastuzumab Biosimilar; Originator Coverage Removals; CHMP Aflibercept Opinion

The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some preferred drug lists in favor of biosimilars and Evernorth will offer an interchangeable ustekinumab biosimilar at no cost to patients; Samsung Bioepis received a positive regulatory opinion for its aflibercept biosimilar.



© 2024 MJH Life Sciences

All rights reserved.